DIA Biosimilars 2013

MorphoSys

MorphoSys, Celgene to jointly develop cancer program

Tuesday, July 2, 2013 01:15 PM

Global biopharma companies MorphoSys and Celgene have agreed to jointly develop MOR202 globally and co-promote it in Europe. MOR202 is a fully human monoclonal antibody targeting CD38 to treat patients with multiple myeloma and certain leukemias. It currently is being evaluated in a phase I/IIa trial in patients with relapsed/refractory myeloma. The companies will collaborate on the development of MOR202 in multiple myeloma and other indications and share costs.

More... »

Cenduit: Now with Patient Reminders

MorphoSys, GSK ink license agreement

Thursday, June 6, 2013 01:35 PM

Pharmaceutical developer MorphoSys has entered into a global agreement with GlaxoSmithKline to develop and commercialize MOR103, MorphoSys's proprietary HuCAL-derived antibody against GM-CSF, which has concluded phase I/II development in mild to moderate rheumatoid arthritis.

More... »

CRF Health – eCOA Forum

MorphoSys, Heptares to develop antibody therapeutics targeting GPCRs

Wednesday, February 13, 2013 10:03 AM

MorphoSys, a biotechnology company focused on fully human antibodies, and Heptares Therapeutics, a developer of new medicines targeting G protein-coupled receptors (GPCRs), have signed an agreement to discover novel antibody therapeutics targeting GPCRs—membrane proteins involved in a broad range of biological processes and diseases.

More... »

MorphoSys completes sale of AbD Serotec to Bio-Rad

Friday, January 11, 2013 01:55 PM

MorphoSys, a biotechnology company focusing on fully human antibodies, has completed the sale of its research and diagnostic antibody segment AbD Serotec to Waltham, Mass.-based Bio-Rad Laboratories.

More... »

Bio-Rad to acquire MorphoSys's research & diagnostics antibody business

Tuesday, December 18, 2012 09:16 AM

MorphoSys, a German biotech focused on human antibodies, has agreed to sell its research and diagnostic antibody segment AbD Serotec to Bio-Rad Laboratories, a multinational manufacturer and distributor of life science research and clinical diagnostic products.

More... »

Boehringer Ingelheim forms partnerships

Wednesday, March 16, 2011 12:53 PM

Boehringer Ingelheim has entered into an antibody deal with fellow German firm MorphoSys and signed a diabetes technology pact with Depomed, according to Pharma Times.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs